Hospital Acquired Infection (HAI) Testing Market Is Witnessing Rapid Growth Worldwide

Hospital associated infection (HAI) testing also called as nosocomial infection testing market is being driven by increasing incidences of multi drug resistant infections acquired at hospitals. These infections are difficult to treat as they are resistant to commonly prescribed drugs. Most common nosocomial infections include urinary tract infections (UTI), surgical site infections, gastrointestinal infections, meningitis and pneumonia. Diagnosis of HAIs in early stages is vital for success of treatment. Hence diagnosis tests play a major role in successful outcome of the treatment. These tests include PCR based tests, ELISA based tests, microarray based tests and others.

Staphylococcus aureus, Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, Respiratory Syncytial Virus, and Candida are some of the major causative agents of hospital acquired infections. Surgical site infections and pneumonia are most common infections acquired at hospitals. Centers for Disease Control and Prevention, U.S. (CDC) estimates that surgical site infections and ventilator associated pneumonia account for over 45% of the total hospital acquired infections in the U.S. The institute also states that chances of hospital infections increases with the length of stay and prolonged exposure to ventilator. Improper sterilization of surgical tools and operating rooms also add to chances of acquiring multi drug resistant infections. Prevalence of nosocomial infections is higher in low and middle income countries where hospital regulatory policies are lenient and awareness about multi drug resistant infections is low. European Center for Disease Prevention and Control (ECDC) estimates that more than 4,100,000 patients in the European Union (EU) are estimated to acquire a healthcare associated infection each year. The organization also suggest that 20% - 30% of hospital acquired infections can be prevented by intensive hygiene and control policies. According to the World Health Organization (WHO), 7-10% of hospitalized patients acquire infection at hospitals globally, and this percentage of higher in developing and under developed economies.

Request Free Report Sample@ http://www.sa-brc.com/Global-Hospital-Acquired-Infection-HAI-Testing-Market-Assessment--Forecast-2017-2021/up120

Hospital acquired infection testing market has been witnessing rapid growth worldwide due to high mortality rate of multi drug resistant infections. Strict control measures and government policies have helped in reducing prevalence of nosocomial infections in the U.S. and other developed countries in the Europe. However countries in Latin America, Asia Pacific and Africa still struggle in curbing the crisis. Hence the market for hospital acquired infection testing is anticipated to grow faster in these regions.

Popularity of genetic testing and advent of sophisticated next generation sequencing devices would revolutionize the hospital testing market. These tests have high accuracy and can deliver results within few hours. Regulatory approval remains a hurdle for the technology to penetrate hospital acquired infection testing market. Key players include bioMerieux, Roche Diagnostics, Qiagen, Thermo Fisher Scientific, Cepheid and others.

Request For TOC@ http://www.sa-brc.com/Global-Hospital-Acquired-Infection-HAI-Testing-Market-Assessment--Forecast-2017-2021/upcomingdetail120

NOTE: This report is currently under research and will be made available to clients on request.